Before the U.S. Food and Drug Administration approved resmetirom (Resdifla), the first liver-targeting drug Metabolic dysfunction-associated steatohepatitis (MASH) Therapeutically, weight loss served as the cornerstone of...
Results from a single-patient gene therapy trial at SickKids are showing promise in halting the progression of a Toronto boy's rare disease. Michael Pirovolakis has spastic...
Recent Comments